» Articles » PMID: 24832848

Risk Factors of Severe Hand, Foot and Mouth Disease: a Meta-analysis

Overview
Publisher Informa Healthcare
Date 2014 May 17
PMID 24832848
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In recent years, outbreaks of hand, foot and mouth disease (HFMD) have increased, and more and more severe cases have appeared. We conducted a meta-analysis to generate large-scale evidence on the risk factors of severe HFMD.

Methods: PubMed, Elsevier Science Direct, China National Knowledge Infrastructure (CNKI), and Wanfang (Chinese) were searched to identify relevant articles. All analyses were performed using Stata 11.0.

Results: We conducted a meta-analysis of 19 separate studies. Duration of fever ≥ 3 days (odds ratio (OR) 10.09, 95% confidence interval (CI) 6.22-16.35), body temperature ≥ 37.5°C (OR 4.91, 95% CI 1.26-19.18), lethargy (OR 7.75, 95% CI 3.78-15.89), hyperglycemia (OR 2.77, 95% CI 2.06-3.71), vomiting (OR 8.83, 95% CI 1.05-74.57), increased neutrophil count (weighted mean difference (WMD) 0.61, 95% CI 0.52-0.70), enterovirus 71 (EV71) infection (OR 5.13, 95% CI 3.11- 8.46), young age (WMD - 0.44, 95% CI - 0.69 to -0.19), and home care (OR 1.65, 95% CI 1.26-2.17) were significantly related to the risk of severe HFMD. We also found that a confirmed diagnosis at first visit to hospital significantly decreased the risk of severe HFMD (OR 0.30, 95% CI 0.09-0.99). We did not find an association between oral rash (OR 1.07, 95% CI 0.82-1.39), increased leukocyte count (WMD 0.51, 95% CI - 0.05-1.06), male sex (OR 1.06, 95% CI 0.91-1.24), or living in a rural area (OR 1.39, 95% CI 0.95-2.02) and the risk of severe HFMD.

Conclusions: Duration of fever ≥ 3 days, body temperature ≥ 37.5°C, lethargy, hyperglycemia, vomiting, increased neutrophil count, EV71 infection, and young age are risk factors for severe HFMD. A confirmed diagnosis at first visit to hospital can significantly decrease the risk of severe HFMD.

Citing Articles

A review of enterovirus-associated hand-foot and mouth disease: preventive strategies and the need for a global enterovirus surveillance network.

Huang C, Su S, Chen K Pathog Glob Health. 2024; 118(7-8):538-548.

PMID: 39229797 PMC: 11892072. DOI: 10.1080/20477724.2024.2400424.


Hand, foot, and mouth disease: could EPs® 7630 be a treatment option? A prospective randomized open-label multicenter clinical study.

Sutcu M, Kara M, Yildiz F, Kilic O, Tural Kara T, Akkoc G Front Pediatr. 2024; 12:1274010.

PMID: 38832001 PMC: 11146204. DOI: 10.3389/fped.2024.1274010.


A CASE REPORT OF HAND AND FOOT SKIN CHANGES RESEMBLING PTU-INDUCED VASCULITIS IN A YOUNG MALE WITH DIFFUSE TOXIC GOITRE.

Tomasovic M, Sinik M, Gluvic Z, Zafirovic S, Isenovic E Acta Endocrinol (Buchar). 2024; 19(3):380-385.

PMID: 38356970 PMC: 10863961. DOI: 10.4183/aeb.2023.380.


Current status of hand-foot-and-mouth disease.

Zhu P, Ji W, Li D, Li Z, Chen Y, Dai B J Biomed Sci. 2023; 30(1):15.

PMID: 36829162 PMC: 9951172. DOI: 10.1186/s12929-023-00908-4.


Hand, Foot, and Mouth Disease: A Narrative Review.

Leung A, Lam J, Barankin B, Leong K, Hon K Recent Adv Inflamm Allergy Drug Discov. 2022; 16(2):77-95.

PMID: 36284392 DOI: 10.2174/1570180820666221024095837.